Fidelity Investments’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $247M | Buy |
6,335,756
+311,003
| +5% | +$10M | 0.01% | 838 |
|
|
2026
Q1 | $196M | Sell |
6,024,753
-533,013
| -8% | -$17.1M | 0.01% | 863 |
|
|
2025
Q4 | $231M | Buy |
6,557,766
+767,715
| +13% | +$27.2M | 0.01% | 807 |
|
|
2025
Q3 | $152M | Sell |
5,790,051
-4,031,846
| -41% | -$120M | 0.01% | 974 |
|
|
2025
Q2 | $260M | Sell |
9,821,897
-1,427,440
| -13% | -$37.6M | 0.01% | 720 |
|
|
2025
Q1 | $272M | Sell |
11,249,337
-5,466,101
| -33% | -$173M | 0.02% | 681 |
|
|
2024
Q4 | $673M | Buy |
16,715,438
+96,008
| +0.6% | +$5.47M | 0.04% | 367 |
|
|
2024
Q3 | $1.05B | Buy |
16,619,430
+79,149
| +0.5% | +$4.64M | 0.06% | 254 |
|
|
2024
Q2 | $877M | Buy |
16,540,281
+192,989
| +1% | +$12.7M | 0.06% | 276 |
|
|
2024
Q1 | $1.34B | Buy |
16,347,292
+1,342,952
| +9% | +$59.8M | 0.09% | 188 |
|
|
2023
Q4 | $279M | Buy |
15,004,340
+16
| +0% | +$209 | 0.02% | 621 |
|
|
2023
Q3 | $166M | Buy |
15,004,324
+28,517
| +0.2% | +$408K | 0.01% | 776 |
|
|
2023
Q2 | $243M | Buy |
14,975,807
+4,053,059
| +37% | +$84.9M | 0.02% | 650 |
|
|
2023
Q1 | $182M | Buy |
10,922,748
+10,920,979
| +617,353% | +$113M | 0.02% | 748 |
|
|
2022
Q4 | $16.6K | Sell |
1,769
-298
| -14% | -$1.33K | ﹤0.01% | 3840 |
|
|
2022
Q3 | $6K | Sell |
2,067
-31
| -1% | -$102 | ﹤0.01% | 4275 |
|
|
2022
Q2 | $6K | Buy |
2,098
+670
| +47% | +$1.66K | ﹤0.01% | 4281 |
|
|
2022
Q1 | $4K | Buy |
1,428
+1,358
| +1,940% | +$4.87K | ﹤0.01% | 4523 |
|
|
2021
Q4 | $0 | Buy |
70
+11
| +19% | +$62 | ﹤0.01% | 4976 |
|
|
2021
Q3 | $0 | Sell |
59
-136
| -70% | -$840 | ﹤0.01% | 5092 |
|
|
2021
Q2 | $1K | Buy |
195
+187
| +2,338% | +$1.11K | ﹤0.01% | 4118 |
|
|
2021
Q1 | $0 | Hold |
8
| – | – | ﹤0.01% | 4575 |
|
|
2020
Q4 | $0 | Sell |
8
-1,600,004
| -100% | -$9.69M | ﹤0.01% | 4315 |
|
|
2020
Q3 | $9.31M | Sell |
1,600,012
-300,025
| -16% | -$2.07M | ﹤0.01% | 1854 |
|
|
2020
Q2 | $13.7M | Sell |
1,900,037
-277,617
| -13% | -$1.84M | ﹤0.01% | 1698 |
|
|
2020
Q1 | $10.2M | Sell |
2,177,654
-8,714
| -0.4% | -$53.6K | ﹤0.01% | 1684 |
|
|
2019
Q4 | $17.5M | Sell |
2,186,368
-768,335
| -26% | -$5.6M | ﹤0.01% | 1649 |
|
|
2019
Q3 | $20.3M | Sell |
2,954,703
-105,626
| -3% | -$785K | ﹤0.01% | 1565 |
|
|
2019
Q2 | $25.4M | Sell |
3,060,329
-10,767
| -0.4% | -$92K | ﹤0.01% | 1523 |
|
|
2019
Q1 | $30.5M | Sell |
3,071,096
-1,988,816
| -39% | -$16.6M | ﹤0.01% | 1414 |
|
|
2018
Q4 | $38.7M | Sell |
5,059,912
-2,165,001
| -30% | -$25.9M | 0.01% | 1252 |
|
|
2018
Q3 | $126M | Buy |
+7,224,913
| New | +$86M | 0.01% | 857 |
|
Other funds holding VKTX
Fidelity Investments's VKTX Position: Q2 2026 in Review
Fidelity Investments increased its Viking Therapeutics (VKTX) stake by 5.2% in Q2 2026, buying an estimated $10M and bringing the position to 6,335,756 shares worth $247M. The position accounts for 0.01% of the portfolio, ranked #838.
Fidelity Investments first reported a position in VKTX in Q3 2018 and has held it in 32 quarters since. The position peaked at $1.34B in Q1 2024. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.
- Fidelity Investments held 6,335,756 shares of Viking Therapeutics worth $247M as of Q2 2026.
- Fidelity Investments bought 311,003 Viking Therapeutics shares in Q2 2026, an estimated $10M.
- Viking Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q2 2026, its #838 holding.
- Fidelity Investments first reported a position in Viking Therapeutics in Q3 2018 and has held it in 32 quarters since.
- Fidelity Investments's Viking Therapeutics position peaked at $1.34B in Q1 2024.
- 434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.